DexCom releases Dexcom ONE real-time Continuous Glucose Monitoring system
DexCom has unveiled their new Dexcom ONE Continuous Glucose Monitoring System which will be launched in the United Kingdom in May. The Dexcom ONE system is an easy-to-use real-time CGM (rt-CGM) for people living with diabetes. Dexcom ONE is currently in review to be added to drug tariffs across the UK regions.
Dexcom ONE, a wearable sensor and transmitter, enables people to control their diabetes. By continuously monitoring glucose levels and sending real-time values wirelessly to a compatible smart device via the Dexcom ONE mobile app, the technology eliminates the need for painful finger pricks. The app was specially designed to be user friendly, displaying trend arrows to show the speed and direction glucose levels are heading, making immediate treatment decisions easier. A range of customisable alerts help users avoid potentially dangerous high or low glucose events.
Dexcom ONE will be part of a range of products offered by DexCom for people with diabetes in the UK that also includes the Dexcom G6 CGM system and the upcoming Dexcom G7 CGM system. Dexcom ONE shares the same sensing hardware as Dexcom G6 and is suitable for people with Type 1 or Type 2 diabetes using insulin.
This news comes as the National Institute for Health and Care Excellence (NICE) announced new guidance for adults and children managing Type 1 diabetes. NICE now recommends that adults with Type 1 diabetes be offered a choice of glucose sensors, including rt-CGM, based on their individual preferences, needs, characteristics, and the functionality of the devices available. Furthermore, the guidance also recom-mends that all children with Type 1 diabetes be offered rt-CGM, together with education for both them and their families and/or carers on how to use their device. This not only improves access to potentially lifesaving technology for people with diabetes, but also provides greater choice.
Karen Baxter, Vice President, UK & Ireland, Benelux, France and Spain at DexCom, commented: “The upcoming launch of Dexcom ONE represents a significant step forward in diabetes management and inclusion on the drug tariff would ensure that more people benefit from this life changing technology. Should Dexcom ONE be added to the NHS drug tariff, DexCom will implement an educational and support programme for people with diabetes and healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and wider availability of Dexcom CGM.”
Dr. Emma Wilmot, Consultant Diabetologist, Derby Teaching Hospitals NHS Foundation Trust; Honorary Associate (clinical) Professor, University of Nottingham and Founder, Diabetes Technology Network UK, said: “For many years, fingerstick blood glucose testing has been a critical component of diabetes self-management; however, self-monitoring can be time-consuming, painful and difficult to fit into a busy day. We welcome the addition of Dexcom ONE rt-CGM as an accessible option for people with diabetes.”
DexCom is headquartered in San Diego, California, and with operations across Europe.
